Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation

Biochemical and Biophysical Research Communications

Volumn 409, Issue 3, 2011, Pages 442-447

  Chou, Ruey Hwang ^a,b,c   Lin, Sheng Chieh ^a,d   Wen, Hui Chin ^a   Wu, Cheng Wen ^a,d,e   Chang, Wun Shaing Wayne ^a,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

CpG methylation; Invasion; Kallikrein; Lung cancer; Migration

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN 13; LAMININ; NERVE CELL ADHESION MOLECULE; P CADHERIN; PLAKOGLOBIN; PLAKOPHILIN; PLAKOPHILIN 4; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; EXTRACELLULAR MATRIX; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; ANIMALS; CADHERINS; CELL MOVEMENT; CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; HUMANS; KALLIKREINS; LAMININ; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80955180553     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.022     Document Type: Article

References (21)

1. Bartoli L., Calabrese R., Fariselli P., Mita D.G., Casadio R. A computational approach for detecting peptidases and their specific inhibitors at the genome level. BMC Bioinf. 2007, 8(Suppl. 1):S3.
2. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 2001, 22:184-204.
3. Diamandis E.P., Yousef G.M. Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 2002, 48:1198-1205.
4. Yousef G.M., Chang A., Diamandis E.P. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J. Biol. Chem. 2000, 275:11891-11898.
5. Chang A., Yousef G.M., Scorilas A., Grass L., Sismondi P., Ponzone R., Diamandis E.P. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br. J. Cancer 2002, 86:1457-1464.
6. Scorilas A., Borgono C.A., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M., Diamandis E.P. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. 2004, 22:678-685.
7. White N.M., Mathews M., Yousef G.M., Prizada A., Popadiuk C., Dore J.J. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br. J. Cancer 2009, 101:1107-1113.
8. White N.M., Mathews M., Yousef G.M., Prizada A., Fontaine D., Ghatage P., Popadiuk C., Dawson L., Dore J.J. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomarkers 2009, 5:279-287.
9. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
10. S.F. Altekruse, C.L. Kosary, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, J. Ruhl, N. Howlader, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, K. Cronin, H.S. Chen, E.J. Feuer, D.G. Stinchcomb, B.K. Edwards, SEER Cancer Statistics Review, 1975-2007, National Cancer Institute, Bethesda, Maryland, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
11. Planque C., de Monte M., Guyetant S., Rollin J., Desmazes C., Panel V., Lemarie E., Courty Y. KLK5 and KLK7 two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem. Biophys. Res. Commun. 2005, 329:1260-1266.
12. Sher Y.P., Chou C.C., Chou R.H., Wu H.M., Wayne Chang W.S., Chen C.H., Yang P.C., Wu C.W., Yu C.L., Peck K. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res. 2006, 66:11763-11770.
13. Planque C., Blechet C., Ayadi-Kaddour A., Heuze-Vourc'h N., Dumont P., Guyetant S., Diamandis E.P., El Mezni F., Courty Y. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. Biol. Chem. 2008, 389:781-786.
14. Fujisawa K., Maesawa C., Sato R., Wada K., Ogasawara S., Akiyama Y., Takeda M., Fujita T., Otsuka K., Higuchi T., Suzuki K., Saito K., Masuda T. Epigenetic status and aberrant expression of the maspin gene in human hepato-biliary tract carcinomas. Lab. Invest. 2005, 85:214-224.
15. Baldassarre M., Pompeo A., Beznoussenko G., Castaldi C., Cortellino S., McNiven M.A., Luini A., Buccione R. Dynamin participates in focal extracellular matrix degradation by invasive cells. Mol. Biol. Cell 2003, 14:1074-1084.
16. Chou R.H., Lin K.C., Lin S.C., Cheng J.Y., Wu C.W., Chang W.S. Cost-effective trapezoidal modified Boyden chamber with comparable accuracy to a commercial apparatus. BioTechniques 2004, 37:724-726.
17. Kanai Y., Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007, 28:2434-2442.
18. Nieman M.T., Prudoff R.S., Johnson K.R., Wheelock M.J. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J. Cell Biol. 1999, 147:631-644.
19. Hazan R.B., Phillips G.R., Qiao R.F., Norton L., Aaronson S.A. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 2000, 148:779-790.
20. Potthoff S., Entschladen F., Niggemann B., Zaenker K.S., Lang K. N-cadherin engagement provides a dominant stop signal for the migration of MDA-MB-468 breast carcinoma cells. Breast Cancer Res. Treat. 2007, 105:287-295.
21. Rieger-Christ K.M., Hanley R., Lodowsky C., Bernier T., Vemulapalli P., Roth M., Kim J., Yee A.S., Le S.M., Marie P.J., Libertino J.A., Summerhayes I.C. The green tea compound, (-)-epigallocatechin-3-gallate downregulates N-cadherin and suppresses migration of bladder carcinoma cells. J. Cell. Biochem. 2007, 102:377-388.